Drugs

# Faricimab: AdisInsight Report

## Key Points

- A bispecific antibody that inhibits both the VEGF-A and Ang-2 pathways has been developed by Roche/Genentech for the treatment of retinal vascular diseases
- Received its first approvals on 28 January 2022 in the USA
- Approved for use in nAMD and DME


## Summary

- Faricimab (faricimab-svoa; Vabysmo™) is a bispecific antibody that binds to and inhibits both vascular endothelial growth factor (VEGF)-A and angiopoietin-2 (Ang-2).
- Administered by intravitreal injection, faricimab is being developed by Roche/Genentech for use in the treatment of retinal vascular diseases.
- In January 2022 faricimab received its first approvals, in the USA, for use in the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) or diabetic macular edema (DME).
- Faricimab is also currently under regulatory review in the EU and Japan for use in nAMD and DME.
- Phase III clinical development of faricimab for use in the treatment of nAMD, DME, and macular edema due to retinal vein occlusion is continuing in multiple other countries worldwide.
- This article summarizes the milestones in the development of faricimab leading to these first approvals for nAMD and DME in the USA.






Shirley, M. *Drugs*. 2022. https://doi.org/10.1007/s40265-022-01713-3